RECURSION PHARMACEUTICALS, INC. Increase (Decrease) in Other Operating Assets
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Increase (Decrease) in Other Operating Assets of -$8.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other operating assets for the quarter ending 2026-06-30 was $6.29M.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was -$14.75M.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other operating assets for the quarter ending 2025-12-31 was $836.00K, a 55.95% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was -$3.53M, a 191.21% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other operating assets for fiscal 2025 was -$32.94M, a 642.56% decline from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other operating assets for fiscal 2024 was $6.07M, a 21.73% decline from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other operating assets for fiscal 2023 was $7.76M, a 387700.00% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other operating assets for fiscal 2022 was $2.00K, a 99.96% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 3 month as first filed | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 6 month as first filed | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 9 month as first filed | Increase (Decrease) in Other Operating Assets 12 month | Increase (Decrease) in Other Operating Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$8.45M 10-Q · filed 2026-08-05 | -$7.62M derived: sum of 3 quarters · filed 2026-08-05 | -$11.15M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$14.75M 10-Q · filed 2026-05-06 | -$13.91M derived: sum of 2 quarters · filed 2026-05-06 | -$17.44M derived: sum of 3 quarters · filed 2026-05-06 | -$42.85M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $836.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$2.69M derived: sum of 2 quarters · filed 2026-02-25 | -$28.10M derived: sum of 3 quarters · filed 2026-08-05 | -$32.94M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | -$3.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$28.94M derived: sum of 2 quarters · filed 2026-08-05 | -$33.77M 10-Q · filed 2025-11-05 | -$31.88M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$25.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$30.25M 10-Q · filed 2026-08-05 | -$28.35M derived: sum of 3 quarters · filed 2026-08-05 | -$24.48M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$4.84M 10-Q · filed 2026-05-06 | -$2.94M derived: sum of 2 quarters · filed 2026-05-06 | $928.00K derived: sum of 3 quarters · filed 2026-05-06 | $192.00K derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $5.77M derived: sum of 2 quarters · filed 2026-02-25 | $5.03M derived: sum of 3 quarters · filed 2026-02-25 | $6.07M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $3.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.13M derived: sum of 2 quarters · filed 2025-11-05 | $4.17M 10-Q · filed 2025-11-05 | $1.24M 10-Q · filed 2024-11-06 | $10.60M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | -$736.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $304.00K 10-Q · filed 2025-08-05 | $6.73M derived: sum of 3 quarters · filed 2026-02-25 | $6.93M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $1.04M 10-Q · filed 2025-05-05 | $7.46M derived: sum of 2 quarters · filed 2026-02-25 | $7.67M derived: sum of 3 quarters · filed 2026-02-25 | $8.48M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $6.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.63M derived: sum of 2 quarters · filed 2026-02-25 | $7.44M derived: sum of 3 quarters · filed 2026-02-25 | $7.76M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $203.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.02M derived: sum of 2 quarters · filed 2024-11-06 | $1.33M 10-Q · filed 2024-11-06 | -$4.24M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-06-30 | $814.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.13M 10-Q · filed 2024-08-08 | -$4.44M derived: sum of 3 quarters · filed 2025-02-28 | -$8.22M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-03-31 | $317.00K 10-Q · filed 2024-05-09 | -$5.25M derived: sum of 2 quarters · filed 2025-02-28 | -$9.03M derived: sum of 3 quarters · filed 2025-02-28 | -$7.23M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | -$5.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$9.35M derived: sum of 2 quarters · filed 2025-02-28 | -$7.55M derived: sum of 3 quarters · filed 2025-02-28 | $2.00K 10-K · filed 2025-02-28 | ||||
| 2022-09-30 | -$3.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.98M derived: sum of 2 quarters · filed 2023-11-09 | $5.57M 10-Q · filed 2023-11-09 | $4.20M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $9.35M 10-Q · filed 2023-08-08 | $7.98M derived: sum of 3 quarters · filed 2024-02-29 | $12.37M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-03-31 | $7.55M 10-Q · filed 2023-05-08 | $6.18M derived: sum of 2 quarters · filed 2024-02-29 | $10.56M derived: sum of 3 quarters · filed 2024-02-29 | $10.10M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2021-12-31 | -$1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.01M derived: sum of 2 quarters · filed 2024-02-29 | $2.55M derived: sum of 3 quarters · filed 2024-02-29 | $5.38M 10-K · filed 2024-02-29 | $5.49M 10-K · filed 2022-03-23 | |||
| 2021-09-30 | $4.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $3.92M derived: sum of 2 quarters · filed 2022-11-08 | $6.75M 10-Q · filed 2022-11-08 | $6.86M 10-Q · filed 2021-11-10 | $7.19M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-06-30 | -$468.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $2.36M 10-Q · filed 2022-08-09 | $2.46M 10-Q · filed 2021-08-13 | $2.80M derived: sum of 3 quarters · filed 2023-02-27 | $2.63M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-03-31 | $2.83M 10-Q · filed 2022-05-10 | $2.92M 10-Q · filed 2021-05-12 | $3.27M derived: sum of 2 quarters · filed 2023-02-27 | $3.10M derived: sum of 3 quarters · filed 2023-02-27 | $3.82M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2020-12-31 | $442.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $269.00K derived: sum of 2 quarters · filed 2023-02-27 | $987.00K derived: sum of 3 quarters · filed 2023-02-27 | $1.12M 10-K · filed 2023-02-27 | $1.11M 10-K · filed 2022-03-23 | |||
| 2020-09-30 | -$173.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $545.00K derived: sum of 2 quarters · filed 2021-11-10 | $677.00K 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $718.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $850.00K 10-Q · filed 2021-08-13 | ||||||
| 2020-03-31 | $132.00K 10-Q · filed 2021-05-12 | |||||||
| 2019-12-31 | -$632.00K 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |